CSPC Pharmaceutical Group is a modern pharmaceutical enterprise with research and production of innovative drugs for the nervous system as its main business, and its main product is butylphthalide which is the first national class I new drug with independent intellectual property rights in the field of cerebrovascular disease treatment in China
CSPC Pharmaceutical Group Enbipu Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise with the research and production of innovative drugs for the nervous system as its main business, and is a national high-tech enterprise.
Butaphthalide is the first national class I new drug with independent intellectual property rights in the field of cerebrovascular disease treatment in China, which fills the gap of no self-developed high-tech drugs in the field of cerebrovascular disease treatment in China. The R&D projects of butylphthalide have been included in the National Natural Science Foundation of China, the 1035 Project, the National 863 Program, the "Eighth Five-Year" and "Ninth Five-Year" National Science and Technology Research Projects, the "Tenth Five-Year" Major Science and Technology Projects for the Modernization of Innovative Drugs and Traditional Chinese Medicine, the "Eleventh Five-Year Plan" National Science and Technology Major Projects and the "Twelfth Five-Year" Major Science and Technology Projects.
In 2009, "butylphthalide raw materials and soft capsules" won the National Science and Technology Progress Award. In 2013, the phase IV clinical trial project of butylphthalein sodium chloride injection made breakthrough progress in the "Twelfth Five-Year Plan" major scientific and technological project, and won the "National Strategic Innovation Product" award. Butadiphthalein series products have also been included in the "National Medical Insurance Catalogue" and "Military-Corps Reasonable Medical Drug Catalogue", and have been successively listed as guiding drugs in the "Guidelines for the Prevention and Treatment of Cerebrovascular Diseases in China", "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2010" and "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2014".
Butadiphthalein is China's first independent innovation drug with sales exceeding 1 billion yuan. On May 17, 2014, Enbipu Pharmaceutical Co., Ltd. won the "China Industry Award", which is known as the "Oscar" of China's industry, because of its outstanding performance.
At present, butylphthalide has nearly 40 domestic invention patents and a number of international PCT (Patent Cooperation Agreement) patents, which are protected in dozens of countries and regions around the world. Butadiphthalein has also successfully authorized its patented technology to Europe, America, South Korea and other markets, and has become a chemical drug that has gone abroad by patent licensing.
